The impact of the COVID-19 pandemic on medications for opioid use disorder services in the U.S. and Canada: a scoping review.
Saved in:
| Title: | The impact of the COVID-19 pandemic on medications for opioid use disorder services in the U.S. and Canada: a scoping review. |
|---|---|
| Authors: | Parker, Daniel G. (AUTHOR), Zentner, Daysi (AUTHOR), Burack, Jacob A. (AUTHOR), Wendt, Dennis C. (AUTHOR) |
| Source: | Drugs: Education, Prevention & Policy. Dec2023, Vol. 30 Issue 6, p529-542. 14p. |
| Subjects: | Substance abuse, Health services accessibility, Systematic reviews, Medical care, Research funding, Opioid analgesics, Thematic analysis, COVID-19 pandemic, Telemedicine |
| Geographic Terms: | Canada, United States |
| Abstract: | Since the arrival of the COVID-19 pandemic, preliminary evidence suggests that rates of opioid use and overdose in North America have only been exacerbated. During this time, healthcare services providing medications for opioid use disorder (MOUD) have faced heightened challenges, rapidly adjusting services in order to continue to provide access to treatment. To better understand the impact of the pandemic on MOUD services in the U.S. and Canada, this scoping review summarizes and synthesizes the existing literature on this topic. Articles were deemed eligible to be included in this review if they met the following three criteria: focused on MOUD services; situated within the COVID-19 pandemic; and situated within the U.S. or Canada. Common themes among the articles that met inclusion included the impacts of MOUD policy changes; the transition to telehealth; challenges to providing MOUD; innovative changes to services; and recommendations for policy and service changes. Many articles supported MOUD regulatory changes, with some finding these changes had increased access to MOUD for underserved populations. There is currently a pressing need to evaluate the impacts on MOUD services in greater depth, as recent changes could have lasting implications on future MOUD regulatory policies and treatment standards. [ABSTRACT FROM AUTHOR] |
| Copyright of Drugs: Education, Prevention & Policy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Since the arrival of the COVID-19 pandemic, preliminary evidence suggests that rates of opioid use and overdose in North America have only been exacerbated. During this time, healthcare services providing medications for opioid use disorder (MOUD) have faced heightened challenges, rapidly adjusting services in order to continue to provide access to treatment. To better understand the impact of the pandemic on MOUD services in the U.S. and Canada, this scoping review summarizes and synthesizes the existing literature on this topic. Articles were deemed eligible to be included in this review if they met the following three criteria: focused on MOUD services; situated within the COVID-19 pandemic; and situated within the U.S. or Canada. Common themes among the articles that met inclusion included the impacts of MOUD policy changes; the transition to telehealth; challenges to providing MOUD; innovative changes to services; and recommendations for policy and service changes. Many articles supported MOUD regulatory changes, with some finding these changes had increased access to MOUD for underserved populations. There is currently a pressing need to evaluate the impacts on MOUD services in greater depth, as recent changes could have lasting implications on future MOUD regulatory policies and treatment standards. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 09687637 |
| DOI: | 10.1080/09687637.2023.2181147 |
